Summary
US29446K1060 Chart
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD).
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Equillium Inc. Dividends
Equillium Inc. Earnings
| 18 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 12 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 11 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 21 Aug 2025 Date | | - Cons. EPS | - EPS |
| 14 Aug 2025 Date | | - Cons. EPS | - EPS |
| 18 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 12 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 11 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 21 Aug 2025 Date | | - Cons. EPS | - EPS |
| 14 Aug 2025 Date | | - Cons. EPS | - EPS |
Equillium Inc. (US29446K1060) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Equillium Inc. ever had a stock split?
Equillium Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bruce D. Steel CEO | XSTU Exchange | US29446K1060 ISIN |
| US Country | 35 Employees | - Last Dividend | - Last Split | 11 Oct 2018 IPO Date |
Overview
Equillium, Inc. is a pioneering clinical-stage biotechnology enterprise committed to the development and commercialization of innovative therapies for autoimmune and immuno-inflammatory disorders that currently lack sufficient medical solutions. Originally established as Attenuate Biopharmaceuticals, Inc., the company underwent a rebranding to Equillium, Inc. in May 2017, marking a new chapter in its mission. Operating from its headquarters in La Jolla, California, since its incorporation in 2017, Equillium stands out in the biotech industry through its targeted approach to addressing severe diseases across various medical specialties including dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology.
Products and Services
- itolizumab (EQ001)
As the flagship candidate of Equillium, Inc., itolizumab (EQ001) embodies a pioneering first-in-class monoclonal antibody specifically engineered to inhibit the immune checkpoint receptor CD6. This innovative therapeutic approach has shown promise across several clinical trials for treating acute graft-versus-host disease currently in Phase III, indicating a significant step forward in immunotherapy. Additionally, itolizumab has completed a Phase I trial for ulcerative colitis and is undergoing a Phase I trial for lupus nephritis, highlighting its versatile potential in addressing a spectrum of autoimmune diseases.
- EQ101
Targeting the treatment of cutaneous T cell lymphoma and alopecia areata, EQ101 has successfully completed phase 1/2 clinical trials. This advancement signifies Equillium's dedicated efforts in expanding its portfolio to include solutions for dermatological and autoimmune conditions by leveraging cutting-edge biotechnological strategies.
- EQ302
With a focus on gastrointestinal indications, EQ302 is another vital component of Equillium’s therapeutic offerings. This development underlines the company's commitment to broadening its impact on immuno-inflammatory disorders, further emphasizing its contribution to advancing medical science in areas of unmet need.
Contact Information
